United States Patent 9,545,436: Claim Scope and U.S. Patent Landscape for rFVIIa-Responsive Platelet Subpopulations
Executive summary
- US 9,545,436 claims a patient-selection and dosing-enablement method for bleeding disorders using recombinant factor VIIa (rFVIIa), where a subject’s platelet population is tested ex vivo to identify a platelet subpopulation with elevated rFVIIa binding capacity (thresholds including ≥5 nm rFVIIa incubation, ≥1% subpopulation fraction, and ≥4-fold binding capacity; dependent claim variants include ~6-fold and ≥3.5-fold under dual-agonist activation).
- The patent’s novelty is less about the pharmacology of rFVIIa and more about a biomarker-driven stratification approach: using platelet rFVIIa binding phenotypes to select subjects likely to benefit from rFVIIa and, in one claim family, to avoid rFVIIa when the phenotype is absent.
- The legal and commercial risk is that this is likely to be treated by courts and the Patent Office as a diagnostic/selection method with potentially tight functional definitions (binding “capacity” fold-change, subpopulation percentage, and assay conditions), while the practical enforceability depends on whether accused parties perform the same incubation conditions, quantitation approach, and binding-capacity comparator.
What does US 9,545,436 claim for rFVIIa bleeding disorder treatment selection?
Answer: The core independent claim is a two-step method: (i) select a subject by incubating their platelet population with at least 5 nm rFVIIa and detecting a platelet subpopulation that meets fraction and binding-capacity thresholds; then (ii) administer therapeutically effective rFVIIa to subjects identified by that platelet-phenotype test.
Claim 1 (biomarker-positive selection + rFVIIa administration)
- Step (a)(i): incubate a platelet population from the subject with ≥5 nm rFVIIa.
- Step (a)(ii): detect a subpopulation comprising ≥1% of platelets where the subpopulation has ≥4-fold higher rFVIIa binding capacity than other platelets in the same population.
- Step (b): administer therapeutically effective rFVIIa to the identified subject.
Commercially: This is a companion-like selection method for rFVIIa use, not a pure product claim on recombinant protein.
Dependent claim boundaries that narrow infringement analyses
- Claim 2: requires ~6-fold higher binding (dependent tightening of the fold threshold).
- Claim 3/8/9/10/11/12/13: cover bleeding disorder categories (hemophilia A/B; inhibitor-associated; non-hemophilia bleeding including trauma, surgeries, factor deficiencies, fibrinogen deficiency, thrombocytopenia, intracerebral hemorrhage, von Willebrand disease) and platelet state qualifiers (activated vs non-activated vs coated).
- Claims 6–7: specify subpopulation size: ≥2% or ≥3% (further narrowing the acceptable test result).
- Claims 4: subject is human.
Claim 14 (biomarker-negative identification + alternative therapy)
Claim 14 flips the selection logic:
- Step (a)(i): incubate platelet population with ≥5 nm rFVIIa.
- Step (a)(ii): determine the subject lacks a subpopulation with ≥1% fraction meeting ≥4-fold binding-capacity threshold.
- Step (b): administer an alternative therapy that does not comprise administration of rFVIIa.
Operational meaning: It claims a decision algorithm: rFVIIa if platelet phenotype is present; avoid rFVIIa if phenotype is absent, and select among specified alternatives.
Claim 20 (dual-agonist activation binding phenotype)
Claim 20 expands the assay context:
- Platelet subpopulation characterized after dual activation by two agonists.
- Detect subpopulation with ≥3.5-fold higher rFVIIa binding capacity versus non-activated platelets from the same subject.
- Then administer rFVIIa.
Litigation relevance: “dual activation,” “two agonists,” and the comparator (non-activated platelets) become key infringement levers.
How does US 9,545,436 define the assay: thresholds, “binding capacity,” and platelet handling?
Answer: The patent is assay-dependent. The claim terms create a structured analytical test framework: (1) rFVIIa incubation concentration threshold (≥5 nm), (2) subpopulation fraction threshold (≥1% with dependent ≥2% or ≥3%), (3) fold increase binding-capacity threshold (≥4-fold with dependent ~6-fold; and ≥3.5-fold under dual activation), and (4) platelet state (activated/non-activated/coated).
The assay parameters create enforceable “process” hooks
- Incubation condition: “incubating… with at least 5 nm of rFVIIa.”
- Detection: “detecting a subpopulation” meeting a quantified fraction.
- Binding quantitation: “binding capacity to rFVIIa” expressed as a fold-over internal comparator within the same platelet population.
- Activation state qualifiers: claims cover both baseline and activated/coated platelets.
Binding “capacity” risk: how broadly might a court read it?
The claims do not specify a measurement modality (flow cytometry, radiolabeled binding, ELISA-like detection, imaging cytometry). This opens two opposing arguments:
- Broad reading: “binding capacity” could include any assay that measures relative binding under the claimed conditions.
- Narrow reading: “binding capacity” may be constrained by the patent’s specification and the typical method used for the invention.
In enforcement, the decisive question usually becomes whether an accused protocol:
- uses ≥5 nm rFVIIa in the incubation,
- identifies platelet subpopulations with ≥1% size,
- and demonstrates a ≥4-fold (or dependent thresholds) increase in binding capacity using the same comparator logic.
What bleeding disorders are covered by the patent claims?
Answer: The claims cover hemophilia A and hemophilia B and a broad set of non-hemophilia bleeding disorders, including trauma-related bleeding, surgical bleeding, coagulation factor deficiencies, dilutional coagulopathy, thrombocytopenia, intracerebral hemorrhage, and von Willebrand disease, including inhibitor-associated variants.
Hemophilia coverage
- Claim 3: hemophilia A or hemophilia B.
- Claim 8: congenital or acquired hemophilia A with inhibitors/autoantibodies to FVIII.
- Claim 9: congenital or acquired hemophilia B with inhibitors/autoantibodies to FIX.
Non-hemophilia and other bleeding indications
- Claim 5: non-hemophilia bleeding disorder with “no unacceptable risk of thrombosis” (adds an explicit safety gating concept).
- Claim 10: enumerates additional conditions:
- trauma blood loss
- FVII deficiency
- FV deficiency
- FX deficiency
- FXI deficiency
- FXIII deficiency
- fibrinogen deficiency
- prothrombin deficiency
- dilutional coagulopathy
- thrombocytopenia
- high-risk surgery blood loss
- intracerebral hemorrhage
- von Willebrand disease and vWD with inhibitors to vWF
Note on claim 21 (Claim 20 dependent)
Claim 21 repeats a broad indication list but ties it to the dual activation selection assay context.
Which platelet phenotype states are claimed: activated, non-activated, or coated?
Answer: The claims explicitly include variants where the detected platelet subpopulation is activated, non-activated, or coated.
Dependent claims as phenotype constraints
- Claim 11: subpopulation platelets are activated.
- Claim 12: subpopulation platelets are non-activated.
- Claim 13: subpopulation platelets are coated.
Enforcement effect: If an accused workflow only tests one platelet state (for example, always activated), then claims limited to another state may not be directly infringed. However, independent claims are broad enough to capture a variety of platelet handling unless the specification narrows the meaning of these terms.
What is the “biomarker negative” alternative therapy claim and what does it cover?
Answer: Claim 14 claims a decision method that identifies subjects lacking the rFVIIa-binding platelet phenotype and directs use of an alternative therapy excluding rFVIIa.
Alternative therapy list in Claim 16
Claim 16 enumerates a non-exhaustive catalog of alternatives, including:
- Prothrombin complex concentrate (PCC) and activated PCC
- recombinant Factor IX and recombinant Factor VIII
- anti-hemophilic factor preparations
- desmopressin
- cryoprecipitated AHF
- fresh frozen plasma (FFP)
- porcine FVIII
- FV variants and FVIIIa variants
- FXa variants
- FXIII
- prothrombin and fibrinogen
- mixtures of coagulation factors
- antibodies mimicking FVIII and FVIII-mimicking peptides/compounds
- TFPI inhibitors (peptides and antibodies) and TFPI inhibitors (compounds)
- anti-coagulant protein inhibitors
Commercial impact: This broadens potential relevance beyond rFVIIa substitution. If rFVIIa is used selectively based on platelet binding phenotype, Claim 14 could capture diagnostic-guided withholding of rFVIIa and selection of other hemostatics.
Does US 9,545,436 read on NovoSeven (rFVIIa) and off-label use?
Answer: The claims are not limited to a specific commercial rFVIIa product; they require administering rFVIIa after performing the claimed platelet-binding selection test.
Product tie-in logic
- rFVIIa is a known biologic/drug class used in congenital hemophilia with inhibitors, acquired hemophilia, and off-label settings.
- US 9,545,436’s enforceability depends on whether a provider performs the claimed ex vivo platelet assay and then uses rFVIIa in accordance with the claimed decision thresholds.
Off-label entry risk
If competitors market or provide protocols that use a platelet-binding stratification and then prescribe rFVIIa accordingly, the method claims are the main infringement target, not the drug label.
When does US 9,545,436 expire and how does that affect generic or biosimilar risk?
Answer: Expiration depends on US application priority, filing date, and PTA/terminal disclaimers. Without the application metadata (priority dates, filing date, PTA, and patent term adjustments), a definitive expiration date cannot be produced from the claim text alone.
Practical impact: Because the claims are method-of-treatment/selection dependent on an assay, timing matters primarily for:
- whether clinicians adopt or stop using the assay-driven rFVIIa selection logic,
- whether assay kits or laboratory-developed tests are offered under a licensing arrangement,
- and whether Paragraph IV-style challenges are relevant (method claims often do not map cleanly to drug ANDAs).
What is the likely novelty vs prior art: platelet binding to rFVIIa
Answer: The likely differentiator is stratifying subjects based on a measurable platelet subpopulation that shows elevated rFVIIa binding capacity and using that stratification to guide rFVIIa administration (or to withhold rFVIIa and use alternatives).
Critical prior art landscape (what examiners typically target)
In this type of claim, the common prior art categories are:
- rFVIIa platelet binding biology: studies showing rFVIIa interaction with platelets and procoagulant activity in various platelet states.
- flow cytometry binding phenotypes: identifying subpopulations of blood cells with differential binding of therapeutic proteins.
- biomarker-guided dosing/selection for hemostatic agents: methods correlating biomarkers with response.
- rFVIIa in hemophilia/inhibitor settings and non-hemophilia bleeding: therapeutic use references that can render indication language obvious even if the selection assay is novel.
Obviousness vulnerability: internal comparator fold-change thresholds
The claim’s use of fold-over “other platelets in the platelet population” could be attacked as:
- an inherent property of heterogeneous platelet populations,
- a routine optimization of assay thresholds,
- or a “results-effective-determination” lacking a demonstrated criticality.
How strong are the claims from a litigation standpoint?
Answer: Strength is concentrated in the detailed thresholds and assay logic. Weakness is likely in claim breadth that could be met by “close-enough” assay substitutions and in the possibility that binding-capacity phenotypes were already described in the literature without explicit clinical decision guidance.
Strength levers
- Specific numeric constraints: ≥5 nm rFVIIa incubation, ≥1% subpopulation, ≥4-fold increase, and dependent thresholds (≥2%, ≥3%, ~6-fold, ≥3.5-fold under dual activation).
- Decision algorithm: positive and negative selection (claims 1 vs 14).
- Assay context: dual agonist activation and platelet state qualifiers.
Weakness levers
- Ambiguity of “binding capacity”: without a defined measurement method, accused infringers can argue non-equivalence if they measure different endpoints (binding vs functional procoagulant response).
- Implementation variability: lab-developed methods may differ in incubation time, wash steps, detection antibody/probe, gating strategy, and “subpopulation” identification mechanics.
- Broad indication coverage: hemophilia and non-hemophilia bleeding categories may be attacked for lack of linkage to the biomarker mechanism.
What patent estate surrounds US 9,545,436: where are the likely gaps and overlaps?
Answer: The patent estate surrounding such claims typically clusters into four buckets:
- rFVIIa formulations and dosing regimens (product claims elsewhere; not the core here).
- assay/biomarker methods (patient selection and platelet phenotype detection).
- clinical use in hemophilia/inhibitor or off-label bleeding (use patents elsewhere).
- downstream commercial diagnostics (assay kits, lab methods, reagents).
From the claim text alone, US 9,545,436 appears centered on biomarker stratification rather than formulation or manufacturing. That means overlap with competitors likely comes from any company developing:
- platelet binding assays as predictors of rFVIIa response,
- decision support tools for rFVIIa use,
- or companion diagnostics seeking regulatory and reimbursement traction.
How does US 9,545,436 compare with other rFVIIa-related patent approaches?
Answer: Relative to typical rFVIIa patents, this one is narrower in biological target and broader in clinical domain:
- It is not primarily a method of making rFVIIa, a formulation, or a classic dosing regimen.
- It is a selection/stratification method anchored to rFVIIa binding phenotype in platelet subpopulations.
- It covers both treatment and treatment avoidance based on the same phenotype logic.
Implication: It is more likely to be licensed or litigated at the protocol/lab workflow level than at the drug product level.
What generic entry risks exist given the assay-based method claims?
Answer: Generic competition for rFVIIa (in a biosimilar sense if rFVIIa is treated as biologic) generally focuses on product equivalence, but method claims create risk for parties who:
- provide clinical guidance using the assay,
- sell or operate diagnostic workflows that directly meet the claim steps,
- or support rFVIIa administration protocols predicated on the claimed platelet phenotype thresholds.
Risk vector is procedural, not chemical:
- A biosimilar manufacturer can still face risk if clinicians adopt the same selection assay and then administer rFVIIa (biosimilar or originator) in accordance with the claims.
What would trigger infringement under US 9,545,436 in practice?
Answer: Infringement would typically require proof that an accused party:
- performs the claimed ex vivo incubation of platelets with ≥5 nm rFVIIa, and
- detects a platelet subpopulation with the claimed fraction and binding-capacity fold criteria, and
- then uses that result to administer therapeutically effective rFVIIa (or, in the negative claim, administers an alternative therapy excluding rFVIIa).
Evidence categories likely used in litigation:
- lab SOPs and instrument settings (incubation conditions, detection readouts)
- gating strategies and subpopulation definitions
- clinical study protocols that describe selection logic
- reimbursement documentation tying ordering of rFVIIa to assay outcomes
Key Takeaways
- US 9,545,436 claims a platelet phenotype-driven selection method for administering rFVIIa in bleeding disorders.
- The protected “core” is the combination of (i) incubation with ≥5 nm rFVIIa, (ii) detection of a platelet subpopulation defined by ≥1% fraction and ≥4-fold (or dependent) binding-capacity thresholds, and (iii) therapeutic decision to administer rFVIIa or withhold rFVIIa and use alternatives.
- The patent’s enforceability hinges on how precisely an accused workflow matches the assay conditions and the quantitative definition of binding capacity and subpopulation fraction.
- The claims are likely to be evaluated as biomarker/selection methods, with obviousness exposure if binding phenotypes and heterogeneous platelet binding behavior to rFVIIa are already known.
FAQs
-
Do the claims cover only hemophilia patients?
No. They expressly include hemophilia A/B and a broad list of non-hemophilia bleeding disorders.
-
Is the patent limited to a specific rFVIIa brand or biologic?
The claims require administering rFVIIa, not a particular manufacturer or product.
-
What matters most for infringement: the fold-change threshold or the assay method?
Both. The claims include numeric thresholds and require detecting a subpopulation with elevated binding capacity under claimed incubation conditions.
-
Can a protocol that avoids ex vivo testing avoid infringement?
The independent claims require selecting subjects by incubating platelet populations and detecting the binding phenotype, so skipping the ex vivo step would generally avoid the claimed method.
-
Does the patent also protect “not using rFVIIa” for some patients?
Yes. Claim 14 covers subjects lacking the rFVIIa-binding platelet phenotype and directs use of alternative therapies that do not comprise rFVIIa.
References
No external sources were cited because the prompt did not provide the patent’s publication/filing data, assignee, specification details, or any prior-art or litigation record needed to produce an accurate, source-backed U.S. patent landscape for US 9,545,436.
